Isabel Carbery
Overview
Explore the profile of Isabel Carbery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
31
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carbery I, Todd O, Selinger C
Aliment Pharmacol Ther
. 2024 Dec;
61(4):746-747.
PMID: 39726187
No abstract available.
2.
Carbery I, Todd O, Hale M, Black C, Clegg A, Selinger C
Aliment Pharmacol Ther
. 2024 Nov;
61(2):246-257.
PMID: 39524008
Background: The number of adults aged over 60 years with inflammatory bowel disease (IBD) is increasing. Frailty, rather than chronological age, may be a better predictor of adverse health outcomes....
3.
Carbery I, Selinger C, Todd O, Sebastian S
J Crohns Colitis
. 2024 Oct;
18(Supplement_2):ii46-ii54.
PMID: 39475079
There are growing numbers of older people with inflammatory bowel diseases [IBD]. These older patients are more likely to have other comorbidities and polypharmacy, which can make recognizing and treating...
4.
Monfared N, Gold M, Carbery I, Laube R, Selinger C
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202041
Maintenance of remission during pregnancy is vital for women with inflammatory bowel disease (IBD). The antenatal safety of novel small molecules for IBD is yet to be ascertained. We aimed...
5.
Baillie S, Limdi J, Bassi A, Fraser A, Parkes G, Scott G, et al.
Frontline Gastroenterol
. 2023 Oct;
14(6):497-504.
PMID: 37854782
Objective: Despite its association with poorer outcomes, opioid use in inflammatory bowel disease (IBD) is not well characterised in the UK. We aimed to examine the extent of opioid use,...
6.
Carbery I, Burdge G, Clark T, Broglio G, Greer D, Alakkari A, et al.
BMJ Open Gastroenterol
. 2023 Feb;
10(1).
PMID: 36813298
Background: We aim to compare the real-life direct and indirect costs of switching patients from intravenous to subcutaneous (SC) CT-P13, an infliximab biosimilar, in a tertiary UK Inflammatory Bowel Disease...
7.
Burdge G, Hardman A, Carbery I, Broglio G, Greer D, Selinger C
J Clin Med
. 2022 Oct;
11(19).
PMID: 36233537
Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to...
8.
Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald T, et al.
Aliment Pharmacol Ther
. 2022 Jun;
56(5):783-793.
PMID: 35768996
Background: During illness, adaptations of the hypothalamic-pituitary-thyroid axis reduce energy expenditure, protein catabolism and modulate immune responses to promote survival. Lower serum free triiodothyronine-to-thyroxine (fT3/fT4) ratio has been linked to...
9.
Carbery I, Selinger C
Aliment Pharmacol Ther
. 2020 Dec;
53(2):346-347.
PMID: 33368516
No abstract available.
10.
Selinger C, Carbery I, Al-Asiry J
Br J Hosp Med (Lond)
. 2018 Dec;
79(12):686-693.
PMID: 30526103
The treatment of inflammatory bowel disease has changed dramatically over the last two decades. The arrival of infliximab as the first biological medicine for inflammatory bowel disease revolutionized its management....